Emerging drugs for graft-versus-host disease

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality following allogeneic stem cell transplantation.
• Current corticosteroid treatments are often insufficient, leading to poor quality of life, increased infection risk, and mortality.
• There is a critical need for novel therapies to improve outcomes in acute and chronic GVHD.

Purpose of the Study:

• To review emerging drugs for the prevention and therapy of graft-versus-host disease (GVHD).
• To discuss the current pre-clinical and clinical data for novel GVHD therapeutic agents.

Main Methods:

• Review of emerging drugs for GVHD prevention and therapy.
• Discussion of cellular therapies.
• Analysis of pre-clinical and clinical data for monoclonal antibodies, interleukin-2, alpha-1 antitrypsin, histone deacetylase inhibitors, tyrosine kinase inhibitors, and proteasome inhibitors.

Main Results:

• Several novel therapeutic agents are in early-phase clinical trials for GVHD.
• Monoclonal antibodies, IL-2, alpha-1 antitrypsin, HDAC inhibitors, TKIs, and proteasome inhibitors are under investigation.
• Alpha-1 antitrypsin, ruxolitinib, and interleukin-2 have shown encouraging preliminary results.

Conclusions:

• Emerging therapies for GVHD show promise but require further randomized controlled trials.
• These novel agents are expected to improve response rates compared to corticosteroids alone.
• Alpha-1 antitrypsin, ruxolitinib, and IL-2 are particularly promising candidates for future GVHD treatment.